AlphAIAlphAI — Financial news for AI agents
247wallst.com$HIMS

Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady

Hims & Hers (HIMS) fell 18% after reporting a Q3 loss and cutting its full-year profit outlook. Revenue rose 48.6% YoY to $890.37M, missing estimates. The company also reduced its 2026 revenue and EBITDA guidance. Novo Nordisk (NVO) and Eli Lilly (LLY) were mentioned in the context of Hims & Hers' strategy.

Original reporting
247wallst.com
Published Nov 10, 2026, 6:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 6:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady — source image
Source · 247wallst.com
Decision brief

The 30-second read

$HIMSBearishHigh
01

Why it matters

The earnings miss and guidance cut triggered an 18% drop, indicating immediate downside risk for traders.

02

Market read

The fresh earnings miss and guidance reduction make HIMS a high‑impact trade idea today.

03

What to watch

Potential upside from upcoming GLP‑1 product launches and cost efficiencies from the weight‑loss strategy shift.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Hims & Hers disclosed Q3 2026 results with a GAAP loss, reduced full‑year guidance, and a shift toward branded GLP‑1 drugs.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Hims & Hers reported a Q3 loss and cut full-year profit outlook, causing an 18% share drop.

Expected impact

likely further pressure as the market prices in weaker earnings and lower outlook

Evidence & confidence

The earnings miss and guidance cut are fresh, material information that moved the stock 18% on the day.

Market effects

Sector

Highlights margin pressure in the telehealth/consumer health subscription sector as peers face similar GLP‑1 pricing challenges.

Regional

U.S. market sees a sell‑off in health‑tech stocks; international exposure may soften the impact.

Global

Signals broader scrutiny of weight‑loss and GLP‑1 business models across the global health‑tech space.

Counterpoint

What could challenge this read

The price decline may be overdone if international subscriber growth sustains revenue momentum.

Key entities

  • company
    Hims & Hers

    Telehealth and consumer health subscription provider reporting Q3 loss and guidance cut.

Read at source← All news

StoryHims & Hers posts 49% revenue jump but cuts 2026 EBITDA outlook for third time

Also covered by

5 outlets

Related articles

$HIMSMed

Five states join the FTC's privacy and billing lawsuit against Hims & Hers

Five states joined the FTC's lawsuit against Hims & Hers, alleging privacy violations and deceptive billing practices. The FTC claims Hims shared health data with third parties and hid cancellation terms. Hims plans to defend itself, calling the new claims 'follow-on' allegations. The company recently reported a 49% revenue increase to $890 million but cut its 2026 profit outlook.

mlq.ai
$HIMSMed

Five more states join FTC privacy complaint against Hims & Hers Health

The FTC and five additional states (Arizona, Florida, Nebraska, Ohio, Wisconsin) joined a complaint against Hims & Hers Health (HIMS), alleging the company shared patient health data with third-party advertisers. Utah and California were previously involved in the complaint. The case highlights potential privacy violations and regulatory risks for HIMS.

seekingalpha.com
$NVOLow

FDA requires eye warning for Ozempic, Zepbound and other GLP-1s

The FDA mandates that manufacturers of GLP-1 drugs, including Novo Nordisk's Ozempic and Wegovy, Eli Lilly's Mounjaro and Zepbound, add warnings about a rare eye condition that may cause vision loss. The agency's review followed a study linking semaglutide to increased risk, though drugmakers and eye doctors note the risk is small and not definitively causal. The FDA advises patients to consult doctors if symptoms arise.

inquisitr.com